Asher Bio

Conventional immunotherapies can activate multiple immune cell types, causing limited efficacy and off-target toxicities due to pleiotropic effects.

Asher Bio develops cis-targeting immunotherapies that selectively activate specific immune cell types to precisely direct immune mediators against disease.

Biopharma companies, clinicians, and patients who use targeted immunotherapy treatments for cancer and other immune-driven diseases.